Cover Image
Market Research Report

Market Spotlight: Osteoarthritis and Osteoarthritis Pain

Published by Datamonitor Healthcare Product code 573559
Published Content info 57 Pages
Delivery time: 1-2 business days
Price
Back to Top
Market Spotlight: Osteoarthritis and Osteoarthritis Pain
Published: January 8, 2020 Content info: 57 Pages
Description

This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2017, there were 308.9 million prevalent cases of osteoarthritis (knee or hip) in adults aged 30 years and older worldwide, and forecasts that number to increase to 358.4 million prevalent cases by 2026. The global prevalence of osteoarthritis is estimated to be 8.2%. The approved drugs in the osteoarthritis space focus on a wide variety of targets. The majority of these therapies are administered via the oral route, with the remainder being topical, intraarticular, and transdermal formulations.

The majority of industry-sponsored drugs in active clinical development for osteoarthritis are in Phase II. Therapies in development for osteoarthritis focus on a wide variety of targets. The largest proportion of pipeline drugs are administered via the intraarticular route.

High-impact upcoming events for drugs in the osteoarthritis space comprise topline Phase II, Phase IIb, and Phase III trial results, an expected PDUFA date for an sNDA, and an expected decentralized approval in the EU.

The overall likelihood of approval of a Phase I osteoarthritis and osteoarthritis pain asset is 11.3%, and the average probability a drug advances from Phase III is 50%. Drugs, on average, take 11.3 years from Phase I to approval in the osteoarthritis and osteoarthritis pain space, as well as in the overall rheumatology (non autoimmune) space.

There have been 45 licensing and asset acquisition deals involving osteoarthritis drugs during 2014-19. The $2,610m collaboration agreement signed in 2016 between Regeneron and Teva Pharmaceuticals to develop and commercialize fasinumab was the largest deal.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for osteoarthritis have been in the early and mid-phases of development, with 57% of trials in Phase I-II, and 43% in Phase III-IV.

The US has a substantial lead in the number of osteoarthritis clinical trials globally. The UK leads the major EU markets, while South Korea has the top spot in Asia.

Clinical trial activity in the osteoarthritis space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for osteoarthritis, with 112 trials.

Pfizer leads industry sponsors with the highest overall number of clinical trials for osteoarthritis

Table of Contents
Product Code: DMKC0179226

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Non-pharmacological treatment
  • Pharmacological treatment
  • Surgery

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • GLPG1972 for Osteoarthritis and Osteoarthritis Pain (July 14, 2019)
  • Multiple Drugs for Osteoarthritis and Osteoarthritis Pain (June 25, 2019)
  • Tanezumab for Osteoarthritis and Osteoarthritis Pain (April 18, 2019)
  • Tanezumab for Osteoarthritis and Osteoarthritis Pain (January 29, 2019)
  • Zilosul for Osteoarthritis and Osteoarthritis Pain (December 18, 2018)
  • Lorecivivint for Osteoarthritis and Osteoarthritis Pain (October 23, 2018)
  • Cartiva SCI for Osteoarthritis and Osteoarthritis Pain (August 27, 2018)
  • Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 16, 2018)
  • Ampion for Osteoarthritis and Osteoarthritis Pain (August 7, 2018)
  • Tanezumab for Osteoarthritis and Osteoarthritis Pain (July 18, 2018)
  • Cingal for Osteoarthritis and Osteoarthritis Pain (June 19, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • FDA Misses Zilretta Goal Date, Flexion Says
  • Global Device Approvals Snapshot: 4-10 June 2019
  • Invossa Approval Revoked As Korea Confirms False Data Submission
  • Invossa Gene Therapy Controversy Grows As Government, Patients Take Action
  • Korea Suspends First Approved Gene Therapy Pending Component Discrepancy Probe
  • Global Device Approvals Snapshot For March 26-April 1, 2019

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • $5bn Galapagos Deal Won't Be Last For Gilead, Says O'Day

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of osteoarthritis (knee or hip), 2017-26
  • Figure 2: Overview of pipeline drugs for osteoarthritis in the US
  • Figure 3: Pipeline drugs for osteoarthritis, by company
  • Figure 4: Pipeline drugs for osteoarthritis, by drug type
  • Figure 5: Pipeline drugs for osteoarthritis, by classification
  • Figure 6: Tanezumab for Osteoarthritis and Osteoarthritis Pain (April 18, 2019): Phase III - OA Safety Study (vs. NSAIDs)
  • Figure 7: Tanezumab for Osteoarthritis and Osteoarthritis Pain (January 29, 2019): Phase III - OA of Hip or Knee (6 Months EU Study)
  • Figure 8: Zilosul for Osteoarthritis and Osteoarthritis Pain (December 18, 2018): Phase IIb - PARA_005 (Knee Pain from Osteoarthritis and BMELs)
  • Figure 9: Lorecivivint for Osteoarthritis and Osteoarthritis Pain (October 23, 2018): Phase IIb - SM04690-OA-04
  • Figure 10: Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 16, 2018): Phase III - FACT LTS & OA
  • Figure 11: Tanezumab for Osteoarthritis and Osteoarthritis Pain (July 18, 2018): Phase III - A4091056 (Severe OA of the Hip or Knee)
  • Figure 12: Cingal for Osteoarthritis and Osteoarthritis Pain (June 19, 2018): Phase III - CINGAL 16-02 (EU)
  • Figure 13: Key upcoming events in osteoarthritis
  • Figure 14: Probability of success in the osteoarthritis pipeline
  • Figure 15: Licensing and asset acquisition deals in osteoarthritis, 2014-19
  • Figure 16: Parent patents in osteoarthritis
  • Figure 17: Clinical trials in osteoarthritis
  • Figure 18: Top 10 drugs for clinical trials in osteoarthritis
  • Figure 19: Top 10 companies for clinical trials in osteoarthritis
  • Figure 20: Trial locations in osteoarthritis
  • Figure 21: Osteoarthritis trials status
  • Figure 22: Osteoarthritis trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of osteoarthritis (knee or hip), 2017-26
  • Table 2: Marketed drugs for osteoarthritis
  • Table 3: Pipeline drugs for osteoarthritis in the US
  • Table 4: GLPG1972 for Osteoarthritis and Osteoarthritis Pain (July 14, 2019)
  • Table 5: Multiple Drugs for Osteoarthritis and Osteoarthritis Pain (June 25, 2019)
  • Table 6: Tanezumab for Osteoarthritis and Osteoarthritis Pain (April 18, 2019)
  • Table 7: Tanezumab for Osteoarthritis and Osteoarthritis Pain (January 29, 2019)
  • Table 8: Zilosul for Osteoarthritis and Osteoarthritis Pain (December 18, 2018)
  • Table 9: Lorecivivint for Osteoarthritis and Osteoarthritis Pain (October 23, 2018)
  • Table 10: Cartiva SCI for Osteoarthritis and Osteoarthritis Pain (August 27, 2018)
  • Table 11: Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 16, 2018)
  • Table 12: Ampion for Osteoarthritis and Osteoarthritis Pain (August 7, 2018)
  • Table 13: Tanezumab for Osteoarthritis and Osteoarthritis Pain (July 18, 2018)
  • Table 14: Cingal for Osteoarthritis and Osteoarthritis Pain (June 19, 2018)
  • Table 15: Historical global sales, by drug ($m), 2014-18
  • Table 16: Forecasted global sales, by drug ($m), 2019-23
Back to Top